Abstract
Hysterectomy is the treatment choice for patients with endometrial cancer, but progesterone may be an acceptable option for young women who wish to preserve their fertility or for women with severe co-morbidities.
Although progestin therapy of low-grade early-stage endometrial carcinoma has been utilized for years, many questions remain unanswered.
Cohort studies show a high chance of disease regression (65–76 %) and encouraging live birth rates (28–35 %). The risk of disease relapse during follow-up is significant but overall outcome and survival are not jeopardized by well controlled temporary conservative treatment.
Young women desiring to pursue this treatment need to undergo thorough counseling, extensive work-up, and close follow-up and should undergo hysterectomy once family planning is complete.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
Duska LR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83(2):388–93.
Gitsch G, et al. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol. 1995;85(4):504–8.
Lajer H, et al. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 2012;91(8):976–82.
Mourits MJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol. 2010;11(8):763–71.
Obermair A, et al. Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. Int J Gynecol Cancer. 2005;15(2):319–24.
Cade TJ, et al. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117(7):879–84.
Baker J, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.
Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1–8.
Lee NK, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109(3):655–62.
Walsh C, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106(4):693–9.
Koskas M, et al. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril. 2012;98(5):1229–35.
Leitao Jr MM, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2009;113(1):105–8.
Daniel AG, Peters 3rd WA. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol. 1988;71(4):612–4.
Sironi S, et al. Myometrial invasion by endometrial carcinoma: assessment by MR imaging. AJR Am J Roentgenol. 1992;158(3):565–9.
Wu LM, et al. Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: a pooled analysis of prospective studies. Eur Radiol. 2013;23(2):435–49.
Manfredi R, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372–8.
Gotlieb WH. Fertility preserving treatments for endometrial cancer: the unanswered questions. Gynecol Oncol. 2013;129(1):1–2.
Kim CH, et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol. 2013;131(3):714–9.
Lancaster JM, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107(2):159–62.
Kauff ND. How should women with early-onset endometrial cancer be evaluated for lynch syndrome? J Clin Oncol. 2007;25(33):5143–6.
Park JY, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868–74.
Penner KR, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012;124(3):542–8.
Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer. 2005;41(5):673–5.
Janzen DM, et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res. 2013;73(15):4697–710.
Thigpen JT, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736–44.
Ramirez PT, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95(1):133–8.
Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004;95(3):762–4.
Laurelli G, et al. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol. 2011;120(1):43–6.
Kim MK, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol. 2013;209(4):358e1–4.
Minig L, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22(3):643–9.
Gunderson CC, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82.
Ashino-Fuse H, et al. Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer. 1989;44(5):859–64.
Ushijima K, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25(19):2798–803.
Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med. 1961;264:216–22.
Gallos ID, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266e1–12.
Park JY, et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol. 2013;129(1):7–11.
Kim ML, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56(2):67–75.
Banno K, et al. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review). Int J Oncol. 2012;40(6):1755–62.
Varma R, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia–a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):169–75.
Montz FJ, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186(4):651–7.
Kim MK, et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol. 2013;130(3):470–3.
Wright JD, et al. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol. 2009;27(8):1214–9.
Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet Gynecol Scand. 1984;63(5):441–50.
Piver MS, et al. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer. 1980;45(2):268–72.
Podratz KC, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol. 1985;66(1):106–10.
Whitney CW, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):4–9.
Fiorica JV, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10–4.
Pandya KJ, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001;24(1):43–6.
Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006;58(3):242–56.
Katsuki Y, et al. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer. 1997;79(1):169–76.
Nakamura M, et al. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol. 1999;386(1):33–40.
Katayama H, et al. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod. 2010;25(11):2851–8.
Shimizu Y, et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod. 2009;15(10):693–701.
Shimizu Y, et al. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids. 2011;76(1–2):60–7.
Yang S, et al. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med. 2011;12(64):205–12.
Ren Y, et al. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet. 2007;175(2):107–16.
Xiong Y, et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 2005;65(7):2684–9.
Balch C, et al. Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2010;2(3):419–47.
Ai Z, et al. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. Cancer. 2010;116(15):3603–13.
Bokhman JV, et al. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol. 1985;20(2):139–55.
Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90(3):434–40.
Kim YB, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997;79(2):320–7.
Imai M, et al. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol. 2001;22(3):217–20.
Kaku T, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001;167(1):39–48.
Wang CB, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002;94(8):2192–8.
Gotlieb WH, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102(4):718–25.
Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril. 2003;80(6):1315–24.
Niwa K, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005;112(3):317–20.
Ota T, et al. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005;15(4):657–62.
Yahata T, et al. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 2006;21(4):1070–5.
Yang YC, et al. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol. 2005;99(2):287–93.
Le Digabel JF, et al. Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey. Gynecol Obstet Fertil. 2006;34(1):27–33.
Elizur SE, et al. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007;88(6):1562–7.
Minaguchi T, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett. 2007;248(1):112–22.
Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31(7):988–98.
Yamazawa K, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 2007;22(7):1953–8.
Li HZ, Chen XN, Qiao J. Letrozole as primary therapy for endometrial hyperplasia in young women. Int J Gynaecol Obstet. 2008;100(1):10–2.
Eftekhar Z, et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer. 2009;19(2):249–52.
Hahn HS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19(6):1068–73.
Han AR, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009;19(1):147–51.
Signorelli M, et al. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG. 2009;116(1):114–8.
Yu M, et al. Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women. Zhonghua Fu Chan Ke Za Zhi. 2006;41(4):242–5.
Mao Y, et al. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril. 2010;93(1):283–5.
Mazzon I, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93(4):1286–9.
Park H, et al. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Arch Gynecol Obstet. 2012;285(2):473–8.
Perri T, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer. 2011;21(1):72–8.
Thigpen T, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Laskov, I., Gotlieb, W.H. (2015). Progestogens in Endometrial Cancer. In: Carp, H. (eds) Progestogens in Obstetrics and Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-319-14385-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-14385-9_11
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14384-2
Online ISBN: 978-3-319-14385-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)